Serum c-erbB-2 in breast cancer patients.
The c-erbB-2 oncogene product in serum (serum c-erbB-2) was measured by an enzyme-immunoassay kit. The 12 U/ml cut-off level was estimated as the mean plus two standard deviations for 250 healthy women. With this cut-off level increased serum c-erbB-2 was found in 12.0% of primary breast cancer cases (n = 25), in 4.9% of non-recurrent breast cancer patients (n = 82), and in 31.4% of patients with recurrent breast cancer (n = 35). In patients with primary and recurrent breast cancer, whose sera were assayed concurrently for serum c-erbB-2, CEA and CA15-3, the positive rates of these markers were fairly similar. However, their combined use significantly increased the sensitivity as compared to the use of any one marker alone.
Watanabe
N
N
Division of Central Clinical Laboratory, Tokai University School of Medicine, Kanagawa, Japan.
Miyamoto
M
M
Tokuda
Y
Y
Kubota
M
M
Ando
Y
Y
Tajima
T
T
Mitomi
T
T
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood* / Q000235:genetics* / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*
D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D018719:Erb-b2 Receptor Tyrosine Kinases